Head-To-Head Contrast: BioLargo (BLGO) & Its Peers
by Tristan Rich · The Markets DailyBioLargo (NASDAQ:BLGO – Get Free Report) is one of 32 publicly-traded companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its rivals? We will compare BioLargo to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, institutional ownership, risk and profitability.
Analyst Ratings
This is a summary of current ratings and target prices for BioLargo and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLargo | 0 | 0 | 0 | 0 | N/A |
| BioLargo Competitors | 139 | 1251 | 1567 | 44 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 13.55%. Given BioLargo’s rivals higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares BioLargo and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BioLargo | $12.23 million | -$3.50 million | -8.16 |
| BioLargo Competitors | $6.84 billion | $211.64 million | 69.50 |
BioLargo’s rivals have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares BioLargo and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLargo | -16.53% | -58.35% | -32.12% |
| BioLargo Competitors | -591.84% | 5.15% | -0.65% |
Risk and Volatility
BioLargo has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s rivals have a beta of 1.81, suggesting that their average stock price is 81% more volatile than the S&P 500.
Institutional & Insider Ownership
0.0% of BioLargo shares are held by institutional investors. Comparatively, 70.6% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by company insiders. Comparatively, 10.6% of shares of all “Chemicals & allied products” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
BioLargo rivals beat BioLargo on 8 of the 10 factors compared.
BioLargo Company Profile
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.